A real-world study published in Advances in Therapy reports that a tiny drug-eluting implant placed during a short glaucoma procedure can halve the need for traditional eyedrop therapy. The approach targets long-term intraocular pressure control while reducing the daily treatment burden that affects adherence and quality of life. The results were framed around routine clinical use rather than trial-only settings, which is particularly relevant for ophthalmic interventions where real-world persistence and dosing interruptions can dilute outcomes. For developers and clinicians, the report adds real-world evidence to the implant category, supporting further evaluation of durability, safety and patient selection across broader populations.